key: cord-0688306-7il23mvv
authors: Fernandes, Guillaume; Devresse, Arnaud; Scohy, Anais; Yombi, Jean Cyr; Belkhir, Leila; De Greef, Julien; De Meyer, Martine; Mourad, Michel; Darius, Tom; Buemi, Antoine; Kabamba, Benoit; Goffin, Eric; Kanaan, Nada
title: Impact of Kidney Transplantation on Humoral Immunity Against SARS-CoV-2: A Case Series From Belgium
date: 2021-08-03
journal: Transplantation
DOI: 10.1097/tp.0000000000003910
sha: d87e7692cec274b08ac144629659c741b6a59502
doc_id: 688306
cord_uid: 7il23mvv

nan

Guillaume Fernandes, MD, 1 Arnaud Devresse, PhD, 1,2 Anais Scohy, PharmD, 3 Jean Cyr Yombi, MD, 2, 4 Leila Belkhir, PhD, 2, 4 Julien De Greef, MD, 2, 4 Martine De Meyer, MD, 2,5 Michel Mourad, PhD, 2, 5 Tom Darius, PhD, 2,5 Antoine Buemi, MD, 2,5 Benoit Kabamba, MD, 2,4 Eric Goffin, MD, 1,2 and Nada Kanaan, MD 1,2 A nti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have shown good efficacy in kidney transplant candidates 1 , contrasting with disappointing results in kidney transplant recipients (KTRs). 2 However, the impact of starting immunosuppressive treatments for KTRs on anti-SARS-CoV-2 humoral immunity has been poorly investigated to date.

We report the evolution of anti-SARS-CoV-2 antibody (Ab) titers in 14 KTRs, transplanted in our center between January 2021 and June 2021, who received at least 1 vaccine dose before KT. We assessed the anti-receptor-binding domain (RBD) Ab titers (Elecsys anti-SARS-CoV-2, Roche Diagnostics GmbH, Mannheim, Germany; positive threshold ≥0.8 U/mL) on the day of transplantation (day 0) and 28 d after (d 28). This work received an institutional review board approval.

Ten patients had received their second dose of either the BNT162b2 (Pfizer-BioNTech, n = 8) or ChAdOx1 nCoV-19 vaccine (AstraZeneca, n = 2) with a mean time of 57 d (range, 25-78) before KT. Four patients had received a single dose of vaccine (Pfizer n = 2, AstraZeneca n = 2) with a mean time of 29 d (range, 15-30) before KT. The mean age was 58 y (range, 32-77) and 57% were male individuals. Twelve patients were on dialysis before transplantation with a mean duration of 54 mo (range, 20-122). One patient had a prior history of COVID-19.

After KT, all patients were treated with an association of tacrolimus (trough levels, 10-13 ng/mL), mycophenolate (500 mg BID), and steroids. Sensitized patients (n = 3) and KTRs who received a graft from a living donor (n = 2) were additionally inducted with thymoglobulin and basiliximab, respectively. None of the patients developed COVID-19 after KT.

On day 0, the mean anti-RBD Ab titer was high (mean ± SEM: 1124 ± 441 U/mL). However, KTRs who had received a single dose of vaccine (n = 4) showed low mean Ab titer (0.83 ± 0.43 U/mL). On day 28, we observed a significant decrease of anti-RBD Ab titers (Figure 1 ). However, Ab titers remained high (514 ± 205 U/mL) compared with those reached in vaccinated KTRs that we previously published. 2 Not surprisingly, the 4 patients who had received a single dose of vaccine had low Ab titer on day 28 (2.85 ± 1.84 U/mL). Interestingly, on day 28, anti-RBD Ab titers in patients inducted with thymoglobulin Letter to the Editor These results suggest that fully vaccinated patients maintain high Ab titers against SARS-CoV-2 in the first month post-KT, even in KTRs receiving induction therapy. It highlights the benefit to vaccinate all candidates before KT. 5 Other studies are required to assess the longterm evolution and the impact of other therapies used in KT (ie, rituximab) on anti-SARS-CoV-2 Ab acquired before KT.

High response rate to BNT162b2 mRNA COVID-19 vaccine among self-care dialysis patients

Disappointing immunization rate after two doses of the BNT162b2 vaccine in a Belgian cohort of kidney transplant recipients

Persistent immunogenicity of the mRNA COVID-19 vaccine in patients vaccinated before kidney transplant

Immediate impact of induction treatment on post-vaccination SARS-Cov-2 serology in kidney transplant recipients

COVID-19-related mortality during the first 60 days after kidney transplantation